Back to top
more

Doximity (DOCS)

(Real Time Quote from BATS)

$57.20 USD

57.20
319,779

-0.73 (-1.26%)

Updated Aug 6, 2025 10:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks News

Zacks Equity Research

VOYA or SLF: Which Is the Better Value Stock Right Now?

VOYA vs. SLF: Which Stock Is the Better Value Option?

Zacks Equity Research

BBD vs. HDB: Which Stock Is the Better Value Option?

BBD vs. HDB: Which Stock Is the Better Value Option?

Zacks Equity Research

GEF vs. PKG: Which Stock Should Value Investors Buy Now?

GEF vs. PKG: Which Stock Is the Better Value Option?

Zacks Equity Research

APELY vs. OLED: Which Stock Is the Better Value Option?

APELY vs. OLED: Which Stock Is the Better Value Option?

Zacks Equity Research

OGN or DOCS: Which Is the Better Value Stock Right Now?

OGN vs. DOCS: Which Stock Is the Better Value Option?

Debanjana Dey headshot

HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth

Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.

Debanjana Dey headshot

DOCS Boosts Client Retention via Workflow Integration and AI Tools

Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.

Indrajit Bandyopadhyay headshot

Doximity Declines 4.4% in a Month: How to Play the Stock Now?

DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?

Indrajit Bandyopadhyay headshot

Doximity Rides on Telehealth Demand: Will This Drive Sales Further?

DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.

Zacks Equity Research

Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up

DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.

Zacks Equity Research

Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates

Doximity (DOCS) delivered earnings and revenue surprises of 40.74% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of 0% and 7.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.

Zacks Equity Research

Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates

Progyny (PGNY) delivered earnings and revenue surprises of 6.67% and 6.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Doximity (DOCS) Gains As Market Dips: What You Should Know

Doximity (DOCS) concluded the recent trading session at $59.39, signifying a +0.1% move from its prior day's close.

Zacks Equity Research

SOLV vs. DOCS: Which Stock Is the Better Value Option?

SOLV vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?

Here is how Coya Therapeutics, Inc. (COYA) and Doximity (DOCS) have performed compared to their sector so far this year.

Zacks Equity Research

Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note

In the closing of the recent trading day, Doximity (DOCS) stood at $56.65, denoting a +0.64% change from the preceding trading day.

Urmimala Biswas headshot

Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? Let's see.

Zacks Equity Research

Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?

Here is how Enhabit (EHAB) and Doximity (DOCS) have performed compared to their sector so far this year.

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Nalak Das headshot

5 Momentum Stocks to Buy for April Despite a Disappointing March

Five stocks have strong momentum for April. These are: APP, MRVL, DOCS, RDDT, VEEV.

John Blank headshot

Making Sense of Trade Wars

We discuss trade wars, versus traditional trade policy.

Zacks Equity Research

Zacks Industry Outlook Highlights Cencora, Doximity and Pediatrix Medical

Cencora, Doximity and Pediatrix Medical are part of the Zacks Industry Outlook article.